A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AVX502, an alphavirus replicon vaccine expressing an influenza HA protein, is a candidate vaccine against influenza.

The objectives of this Phase 1 study are to test the safety of the vaccine and the immune response to the vaccine in healthy volunteers 18-40 years of age. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in each arm on one or two occasions over 2 months. The study will last 4 months and will have a total of 8 visits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled Phase 1/2 study of the safety and immunogenicity of AVX502 vaccine at two dosage levels and two routes of administration in healthy volunteers conducted at a single research center. A total of 216 participants will be enrolled. Participants will be randomized to receive active vaccine at one of two dosage levels or placebo in a 4:4:1 ratio. Within each active dosage level or placebo subgroup, participants will be randomized to receive their injections by either IM or SC injection in a 1:1 ratio, and will also be randomized to receive either 1 injection (at Week 0) or 2 injections (1 at each of two visits at Weeks 0 and 8) in a 1:1 ratio. Vaccine will be administered by a study nurse in an outpatient setting and all participants will be followed for 4 months after the first immunization. Safety data will include local and systemic reactogenicity after each dose of vaccine, collected in a systematic format using a subject memory aid and a standard grading scale, specific safety laboratory parameters and general AEs. Immunogenicity data will be obtained by collecting blood at defined time points before and after immunization and separating serum (for measurement of antibodies to HA by ELISA and hemagglutination inhibition assays and to the vaccine vector by a VRP neutralization assay) and peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses to HA peptides).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Influenza Flu A/Wyoming/03/2003 Alphavirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Intervention Type BIOLOGICAL

2 doses of placebo given at T=0 and 8 weeks via the SC route

2 doses of placebo given at T=0 and 8 weeks via the SC route

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Between 18 and 40 years of age, inclusive;
2. Good general health without significant physical examination findings or clinically significant abnormal laboratory results;
3. Available to participate for the entire study period of approximately 4 months;
4. For women of childbearing potential, a negative urine pregnancy test at screening and before each immunization, and agreement to consistently use contraception from 28 days prior to enrollment until the last protocol visit, for sexual activity that could lead to pregnancy;
5. Acceptable laboratory parameters: hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for men, white blood cell count 3,300 - 12,000 cells/mm3, platelet count 125,000 - 550,000/mm3, alanine aminotransferase (ALT) within normal range for study laboratory, serum creatinine within normal range for study laboratory, normal urine dipstick (negative glucose, negative hemoglobin, and negative or trace protein), negative hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests, negative HIV blood test;
6. Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available
7. Willingness to participate in the study as evidenced by signed informed consent obtained before screening.

Exclusion Criteria

1. Venous access deemed inadequate for the phlebotomy demands of the study;
2. Women who are breast feeding;
3. In female subjects, a positive urine pregnancy test at screening or on the day of any vaccine injection;
4. Receipt of any influenza vaccine within 12 months prior to enrollment;
5. Receipt of any other vaccine within 30 days prior to enrollment;
6. Use of any investigational agent within 30 days prior to enrollment;
7. Receipt of immunoglobulin or blood products within 60 days prior to enrollment;
8. Use of cytotoxic medications within 6 months prior to enrollment;
9. Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment);
10. Presence of any factor that places the individual at increased risk for severe complications from influenza;
11. History of serious adverse reactions to any vaccine, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema or abdominal pain;
12. History of autoimmune disease;
13. History of splenectomy;
14. History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment);
15. Psychiatric condition that may interfere with the ability to comply with the protocol requirements. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years;
16. History of medical, occupational or family problems as a result of alcohol or illicit drug use during the past 12 months;
17. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AlphaVax, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert A Olmsted, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

AlphaVax, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johnson County Clin-Trials

Lenexa, Kansas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AVX502-002

Identifier Type: -

Identifier Source: org_study_id

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

T1

AVX502

T2

AVX502

T3

AVX502

T4

AVX502

T5

AVX502

T6

AVX502

T7

AVX502

T8

AVX502

C1

Placebo

C2

Placebo

C3

Placebo

C4

Placebo

Interventions

AVX502

AVX502

AVX502

AVX502

AVX502

AVX502

AVX502

AVX502

Placebo

Placebo

Placebo

Placebo

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

AlphaVax, Inc.

Responsible Party

Principal Investigators

Robert A Olmsted, Ph.D.

Locations

Johnson County Clin-Trials

Countries

Related Links

Other Identifiers

AVX502-002